Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.

Therapeutic targeting of the beta-adrenergic receptors has recently shown remarkable efficacy in the treatment of benign vascular tumors such as infantile hemangiomas. As infantile hemangiomas are reported to express high levels of beta adrenergic receptors, we examined the expression of these recep...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jessica M Stiles, Clarissa Amaya, Steven Rains, Dolores Diaz, Robert Pham, James Battiste, Jaime F Modiano, Victor Kokta, Laura E Boucheron, Dianne C Mitchell, Brad A Bryan
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
R
Q
Acceso en línea:https://doaj.org/article/4b2b549a97aa468090e7e8cace6fc211
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:4b2b549a97aa468090e7e8cace6fc211
record_format dspace
spelling oai:doaj.org-article:4b2b549a97aa468090e7e8cace6fc2112021-11-18T07:51:32ZTargeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.1932-620310.1371/journal.pone.0060021https://doaj.org/article/4b2b549a97aa468090e7e8cace6fc2112013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23555867/?tool=EBIhttps://doaj.org/toc/1932-6203Therapeutic targeting of the beta-adrenergic receptors has recently shown remarkable efficacy in the treatment of benign vascular tumors such as infantile hemangiomas. As infantile hemangiomas are reported to express high levels of beta adrenergic receptors, we examined the expression of these receptors on more aggressive vascular tumors such as hemangioendotheliomas and angiosarcomas, revealing beta 1, 2, and 3 receptors were indeed present and therefore aggressive vascular tumors may similarly show increased susceptibility to the inhibitory effects of beta blockade. Using a panel of hemangioendothelioma and angiosarcoma cell lines, we demonstrate that beta adrenergic inhibition blocks cell proliferation and induces apoptosis in a dose dependent manner. Beta blockade is selective for vascular tumor cells over normal endothelial cells and synergistically effective when combined with standard chemotherapeutic or cytotoxic agents. We demonstrate that inhibition of beta adrenergic signaling induces large scale changes in the global gene expression patterns of vascular tumors, including alterations in the expression of established cell cycle and apoptotic regulators. Using in vivo tumor models we demonstrate that beta blockade shows remarkable efficacy as a single agent in reducing the growth of angiosarcoma tumors. In summary, these experiments demonstrate the selective cytotoxicity and tumor suppressive ability of beta adrenergic inhibition on malignant vascular tumors and have laid the groundwork for a promising treatment of angiosarcomas in humans.Jessica M StilesClarissa AmayaSteven RainsDolores DiazRobert PhamJames BattisteJaime F ModianoVictor KoktaLaura E BoucheronDianne C MitchellBrad A BryanPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 3, p e60021 (2013)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Jessica M Stiles
Clarissa Amaya
Steven Rains
Dolores Diaz
Robert Pham
James Battiste
Jaime F Modiano
Victor Kokta
Laura E Boucheron
Dianne C Mitchell
Brad A Bryan
Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.
description Therapeutic targeting of the beta-adrenergic receptors has recently shown remarkable efficacy in the treatment of benign vascular tumors such as infantile hemangiomas. As infantile hemangiomas are reported to express high levels of beta adrenergic receptors, we examined the expression of these receptors on more aggressive vascular tumors such as hemangioendotheliomas and angiosarcomas, revealing beta 1, 2, and 3 receptors were indeed present and therefore aggressive vascular tumors may similarly show increased susceptibility to the inhibitory effects of beta blockade. Using a panel of hemangioendothelioma and angiosarcoma cell lines, we demonstrate that beta adrenergic inhibition blocks cell proliferation and induces apoptosis in a dose dependent manner. Beta blockade is selective for vascular tumor cells over normal endothelial cells and synergistically effective when combined with standard chemotherapeutic or cytotoxic agents. We demonstrate that inhibition of beta adrenergic signaling induces large scale changes in the global gene expression patterns of vascular tumors, including alterations in the expression of established cell cycle and apoptotic regulators. Using in vivo tumor models we demonstrate that beta blockade shows remarkable efficacy as a single agent in reducing the growth of angiosarcoma tumors. In summary, these experiments demonstrate the selective cytotoxicity and tumor suppressive ability of beta adrenergic inhibition on malignant vascular tumors and have laid the groundwork for a promising treatment of angiosarcomas in humans.
format article
author Jessica M Stiles
Clarissa Amaya
Steven Rains
Dolores Diaz
Robert Pham
James Battiste
Jaime F Modiano
Victor Kokta
Laura E Boucheron
Dianne C Mitchell
Brad A Bryan
author_facet Jessica M Stiles
Clarissa Amaya
Steven Rains
Dolores Diaz
Robert Pham
James Battiste
Jaime F Modiano
Victor Kokta
Laura E Boucheron
Dianne C Mitchell
Brad A Bryan
author_sort Jessica M Stiles
title Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.
title_short Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.
title_full Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.
title_fullStr Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.
title_full_unstemmed Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.
title_sort targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.
publisher Public Library of Science (PLoS)
publishDate 2013
url https://doaj.org/article/4b2b549a97aa468090e7e8cace6fc211
work_keys_str_mv AT jessicamstiles targetingofbetaadrenergicreceptorsresultsintherapeuticefficacyagainstmodelsofhemangioendotheliomaandangiosarcoma
AT clarissaamaya targetingofbetaadrenergicreceptorsresultsintherapeuticefficacyagainstmodelsofhemangioendotheliomaandangiosarcoma
AT stevenrains targetingofbetaadrenergicreceptorsresultsintherapeuticefficacyagainstmodelsofhemangioendotheliomaandangiosarcoma
AT doloresdiaz targetingofbetaadrenergicreceptorsresultsintherapeuticefficacyagainstmodelsofhemangioendotheliomaandangiosarcoma
AT robertpham targetingofbetaadrenergicreceptorsresultsintherapeuticefficacyagainstmodelsofhemangioendotheliomaandangiosarcoma
AT jamesbattiste targetingofbetaadrenergicreceptorsresultsintherapeuticefficacyagainstmodelsofhemangioendotheliomaandangiosarcoma
AT jaimefmodiano targetingofbetaadrenergicreceptorsresultsintherapeuticefficacyagainstmodelsofhemangioendotheliomaandangiosarcoma
AT victorkokta targetingofbetaadrenergicreceptorsresultsintherapeuticefficacyagainstmodelsofhemangioendotheliomaandangiosarcoma
AT lauraeboucheron targetingofbetaadrenergicreceptorsresultsintherapeuticefficacyagainstmodelsofhemangioendotheliomaandangiosarcoma
AT diannecmitchell targetingofbetaadrenergicreceptorsresultsintherapeuticefficacyagainstmodelsofhemangioendotheliomaandangiosarcoma
AT bradabryan targetingofbetaadrenergicreceptorsresultsintherapeuticefficacyagainstmodelsofhemangioendotheliomaandangiosarcoma
_version_ 1718422848164331520